We saw some investments this week in New England regenerative medicine, diagnostics, and medical devices companies.
—Cambridge, MA-based Flagship Ventures formed a new partnership with Merck Research Ventures Fund to find and finance companies developing drugs for unmet medical needs. The $250 million Merck fund was established last fall and has so far made four other fund-to-fund investments.
—The Irish pharmaceutical company Shire acquired the assets of Cambridge-based regenerative medicine startup Pervasis Therapeutics for an undisclosed upfront payment, and milestones that could reach $200 million. Pervasis is developing a product for improving blood vessel access in hemodialysis patients.
—Filings with the SEC this week show a couple of area companies have raised some new cash. Pittsfield, MA-based Nuclea Biotechnologies, a developer of cancer diagnostics technology, nabbed $1.9 million in equity- and options-based funding from 15 investors. And Seventh Sense Biosystems, a maker of devices for collecting blood samples, pulled in $750,000 in a debt and rights offering from five backers.